Removable Partial Dentures Made of PEEK
Launched by UNIVERSITY HOSPITAL HEIDELBERG · Dec 19, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of removable partial dentures made from a material called PEEK, designed for people who have lost teeth. The researchers want to find out how well these dentures work over a three-year period by looking at any problems that might arise and how they affect the patients' quality of life. A total of 25 patients from two different hospitals will take part in this study.
To be eligible for the trial, participants should need a removable partial denture that uses clasps for support. However, the study cannot include minors, pregnant or breastfeeding women, people with serious health issues, those who have allergies to the materials used, or anyone who might not follow the study guidelines. During the trial, participants will receive the dentures and will be regularly checked to see how they are doing and how the dentures are impacting their daily lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Indication for a clasp-anchored removable partial denture
- Exclusion Criteria:
- • Minors and adults unable to give consent
- • Pregnancy or breastfeeding
- • Severe general illnesses
- • Allergies or other intolerances to one of the materials used (PEEK, PMMA)
- • Suspicion of lack of compliance
About University Hospital Heidelberg
University Hospital Heidelberg is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key player in translational medicine, the hospital integrates cutting-edge scientific discoveries with patient care, facilitating a robust environment for clinical trials. With a diverse range of specialties and a multidisciplinary approach, University Hospital Heidelberg aims to improve therapeutic outcomes and enhance the quality of life for patients through evidence-based practices. The institution is dedicated to fostering collaborations with academic partners, industry stakeholders, and regulatory bodies to drive forward-looking research initiatives and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Patients applied
Trial Officials
Peter Rammelsberg, Prof. / Head
Study Chair
University Hospital Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported